在质母细胞瘤中准巨细胞和微质细胞的治疗潜力
Fei Zhou1, Pritha Mukherjee1, Jinming Mu1
1Department of Cancer Biology, Lerner Research Institute, Cleveland Clinic, Cleveland, OH, USA.
Trends in pharmacological sciences
|August 10, 2025
概括
向质母细胞瘤 (GBM) 中的瘤相关巨细胞 (TAM) 是一个有希望的策略. 调节TAM可以克服对标准护理和免疫疗法的抵抗,改善这种侵袭性脑癌患者的治疗结果.
科学领域:
- 神经瘤学神经瘤学
- 免疫学 免疫学 免疫学
- 癌症生物学 癌症生物学
背景情况:
- 质母细胞瘤 (GBM) 是一种对当前治疗有抗性的成年大脑瘤.
- 与瘤相关的巨细胞和微质细胞 (TAMs) 是GBM瘤微环境 (TME) 中最丰富的细胞,促进瘤生长和治疗耐药性.
研究的目的:
- 审查最近在GBM中针对TAM生物学方面的进展.
- 探索如何向TAM可以提高护理标准 (SOC) 和免疫疗法疗效.
主要方法:
- 关于GBM中TAM的最新研究的文献综述.
- 对TAM异质性的分析,包括细胞身份和亚群.
- 检查TAM功能:透,重编程,生存和细胞化.
主要成果:
- TAMs显著影响GBM的进展,免疫抑制和治疗耐药性.
- 在GBM TME中,TAM表现出相当大的异质性.
- 针对TAMs是一个可行的治疗途径.
结论:
- 针对TAM透,重编程和TME内部的交互是GBM的一个有希望的战略.
- 对TAM生物学的药理学调制可能会改善GBM治疗结果.
- 对TAM向策略的进一步研究是有必要的,以提高SOC和免疫疗法的有效性.
相关概念视频
Cancer Stem Cells and Tumor Maintenance
Early diagnosis and treatment can often cure cancer. However, even with treatment, residual cells called cancer stem cells (CSC) might remain, often causing tumor recurrence. These cancer stem cells possess the potential for self-renewal and multi-lineage differentiation and are often responsible for the therapeutic resistance displayed in most cancers.
Cancer stem cells are thought to originate from tissue-specific normal stem cells or progenitor cells. The normal stem cells usually reside in...
Cancer stem cells are thought to originate from tissue-specific normal stem cells or progenitor cells. The normal stem cells usually reside in...
Targeted Cancer Therapies
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
There are several types of targeted therapies against specific...


